Although initial observational studies suggested high hopes for drug efficacy, a randomized, double-blind, placebo-controlled clinical trial was unable to prove statistical significance for reducing the following among severe COVID-19 patients hospitalized in Wuhan, China:

• Clinical improvement
• Clearance of virus
• Mortality rates The investigators were forced to stop the study early after no additional patients met the eligibility criteria. The trial was deemed underpowered (58% power), therefore limiting study findings.